ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy

BACKGROUND. Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well‐established therapy target in non‐small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non‐NSCLC tumors and report their responsiveness...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Ross, Jeffrey S., Ali, Siraj M., Fasan, Omotayo, Block, Jared, Pal, Sumanta, Elvin, Julia A., Schrock, Alexa B., Suh, James, Nozad, Sahar, Kim, Sungeun, Jeong Lee, Hwa, Sheehan, Christine E., Jones, David M., Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Miller, Vince A., Stephens, Philip J., Gay, Laurie M.
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Cancer Diagnostics and Molecular Pathology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728036/
https://ncbi.nlm.nih.gov/pubmed/29079636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0488
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares